Drug Recall: Simvastatin tablets due to manufacturing deviations
RemedyRepack Inc. is recalling Simvastatin 40 mg tablets nationwide due to manufacturing deviations. The voluntary recall was initiated in March 2023.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This recall meets the rubric criterion for Score 2 (Moderate): a voluntary precautionary recall with FDA Class II classification and no reported illnesses or injuries.
Plain-English summary
RemedyRepack Inc. is recalling Simvastatin 40 mg tablets distributed nationwide within the United States. The recalled product was packaged in two formats: 30-count bottles (NDC 70518-0060-01) and 90-count bottles (NDC 70518-0060-00).
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations. The specific nature of these manufacturing deviations was not disclosed in the FDA notice.
Multiple lot numbers are affected, with expiration dates ranging from July 2023 through March 2025. The recall was voluntary and initiated by RemedyRepack Inc. on March 20, 2023, with the FDA classifying it as Class II on March 31, 2023. The recall was terminated on October 19, 2023.
Consumers with affected Simvastatin tablets should consult their healthcare provider or pharmacist about whether their medication may be involved and what steps to take.
The recalled product
- Product
- Simvastatin 40 mg tablets, packaged in a) 30-count bottles (NDC 70518-0060-01) and b) 90-count bottles (NDC 70518-0060-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Statin
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # a): J0656821-103122
- Exp. Date 11/30/2023
- J0638547-080922
- Exp. Date 08/31/2023
- J0633575-071822
- Exp. Date 07/31/2023 Lot #: b): B1965081-111622
- Exp. Date 03/31/2025
- B1857922-091922
- B1765298-071322
- B1786319-072922
- B1706842-053122
- Exp. Date 04/30/2023
- B2003311-120822
- Exp. Date 04/30/2025
- B1955679-111122
- Exp. Date 02/28/2025
- B1878942-092922
- Exp. Date 11/30/2024
- B1823203-082622. Exp. Date 10/31/2024
- B1706843-053122
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27